Citation Impact
Citing Papers
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
2013 Standout
Prognostic Factors of Disease-Free Survival after Thyroidectomy in 170 Young Patients with a RET Germline Mutation: A Multicenter Study of the Groupe Français d'Etude des Tumeurs Endocrines
2010
Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
2009 Standout
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: Developmental culling and cancer
2005 StandoutNobel
The Diagnostic Value of Calcitonin Measurement in Wash-out Fluid from Fine-Needle Aspiration of Thyroid Nodules in the Diagnosis of Medullary Thyroid Cancer
2013
A New Hot Spot for Mutations in theretProtooncogene Causing Familial Medullary Thyroid Carcinoma and Multiple Endocrine Neoplasia Type 2A1
1998
Genotype-phenotype correlations in Hungarian patients with hereditary medullary thyroid cancer
2006
A Cys634Gly substitution of the RET proto‐oncogene in a family with recurrence of multiple endocrine neoplasia type 2A and cutaneous lichen amyloidosis
1997
Italian consensus for the classification and reporting of thyroid cytology
2014 Standout
Pheochromocytoma in multiple endocrine neoplasia type 2: European study
1995
Peak Incidence of Pheochromocytoma and Primary Hyperparathyroidism in Multiple Endocrine Neoplasia 2: Need for Age-Adjusted Biochemical Screening
2013
Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome
1997 Standout
The Clinical Presentation (Symptoms and Signs) of Sporadic and Familial Chromaffin Cell Tumours (Phaeochromocytomas and Paragangliomas)
2003
Genetic aberrance of sporadic MEN 2A component tumours: analysis of RET
2005
Pheochromocytomas in von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2 Display Distinct Biochemical and Clinical Phenotypes
2001
The von Hippel–Lindau Tumor Suppressor Gene
2001 StandoutNobel
High penetrance of pheochromocytoma in multiple endocrine neoplasia 2 caused by germ line RET codon 634 mutation in Japanese patients
2013
RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan
2004
Familial medullary thyroid carcinoma: Not a distinct entity? Genotype-phenotype correlation in a large family
1996
Recent Insights into the Molecular Pathogenesis of Pheochromocytoma and Paraganglioma
2006 StandoutNobel
Novel point mutation in exon 10 of theRET proto-oncogene in a family with medullary thyroid carcinoma
1998
Two Germline Missense Mutations at Codons 804 and 806 of the RET Proto‐oncogene in the Same Allele in a Patient with Multiple Endocrine Neoplasia Type 2B without Codon 918 Mutation
1999
Molecular basis of the VHL hereditary cancer syndrome
2002 StandoutNobel
Phaeochromocytoma
2005 Standout
The Genetic Basis of Pheochromocytoma
2003
Defects in enteric innervation and kidney development in mice lacking GDNF
1996 StandoutNature
A Two-Hit Model for Development of Multiple Endocrine Neoplasia Type 2B by RET Mutations
2000
Nine Novel Germline Gene Variants in the RET Proto-Oncogene Identified in Twelve Unrelated Cases
2005
Medullary Thyroid Carcinoma
2007
Presentation of a kindred with familial medullary thyroid carcinoma and Cys611Phe mutation of the RET proto-oncogene demonstrating low grade malignancy
2001
Gene Mutations in the Succinate Dehydrogenase Subunit SDHB Cause Susceptibility to Familial Pheochromocytoma and to Familial Paraganglioma
2001 Standout
von Hippel-Lindau Disease
1997 StandoutNobel
Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto‐oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal
2006
A Novel Point Mutation in the Intracellular Domain of theretProtooncogene in a Family with Medullary Thyroid Carcinoma1
1997
Sporadic Medullary Microcarcinoma of the Thyroid: A Retrospective Analysis of Eighty Cases
1998
2007 Guidelines for the Management of Arterial Hypertension
2007 Standout
RET mutations in human disease
1996
Germ line mutation analysis in families with multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma
1998
Estimated Risk of Pheochromocytoma Recurrence After Adrenal-Sparing Surgery in Patients With Multiple Endocrine Neoplasia Type 2A
2006
Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein
1999 StandoutNobel
A Novel Somatic Mutation in the RET Proto‐oncogene in Familial Medullary Thyroid Carcinoma with a Germline Codon 768 Mutation
1997
von Hippel-Lindau disease
2003 Standout
TheRETProto-Oncogene in Multiple Endocrine Neoplasia Type 2 and Hirschsprung's Disease
1996
Mutation of RET codon 768 is associated with the FMTC phenotype
1997
When should thyroidectomy be performed in familial medullary thyroid carcinoma gene carriers with non-cysteine RET mutations?
2003
Mutations of theRET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease
1997
RET proto-oncogene mutations affecting codon 790/791: A mild form of multiple endocrine neoplasia type 2A syndrome?
2002
Pheochromocytoma in multiple endocrine neoplasia type 2: a prospective study
2001
Presymptomatic thyroidectomy in multiple endocrine neoplasia 2a
2005
Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma
2001
Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility
2010 StandoutNobel
A Novel Point Mutation of theRETProtooncogene Involving the Second Intracellular Tyrosine Kinase Domain in a Family with Medullary Thyroid Carcinoma
2004
Occurrence of MEN 2a in familial hirschsprung's disease: A new indication for genetic testing of the RET proto-oncogene
1998
Hirschsprung Disease in MEN 2A: Increased Spectrum of RET Exon 10 Genotypes and Strong Genotype--Phenotype Correlation
1998
Loss of Heterozygosity at theRETProtooncogene Locus in a Case of Multiple Endocrine Neoplasia Type 2A1
2001
Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL
1997
Pheochromocytoma: The Expanding Genetic Differential Diagnosis
2003
Prophylactic Thyroidectomy in Multiple Endocrine Neoplasia Type 2A
2005
False serum calcitonin high levels using a non-competitive two-site IRMA
2001
The von Hippel–Lindau protein, HIF hydroxylation, and oxygen sensing
2005 StandoutNobel
Pheochromocytoma: Update on Diagnosis, Localization, and Management
1995
Incidence and Prognosis of Syncope
2002 Standout
Effects of exercise-focused versus weight-focused maintenance programs on the management of obesity
1999
Molecular genetic diagnostic program of multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma syndromes in Hungary
2001
Multiple endocrine neoplasia type 2 andRET: from neoplasia to neurogenesis
2000
A census of human cancer genes
2004 Standout
Very early detection of RET proto‐oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children
2002
Multiple endocrine neoplasia type 2 and the RET protooncogene: From bedside to bench to bedside
2005
Prophylactic thyroidectomy in multiple endocrine neoplasia: the impact of molecular mechanisms of RET proto-oncogene
2003
Age at Diagnosis of Pheochromocytoma Differs According to Catecholamine Phenotype and Tumor Location
2010
A Five-Year Report on Experience in the Detection of Pheochromocytoma
2000
Update on the MEN 2A c804 RET mutation: Is prophylactic thyroidectomy indicated?
2000
The RET Mutation E768D Confers a Late-onset Familial Medullary Thyroid Carcinoma – Only Phenotype with Incomplete Penetrance: Implications for Screening and Management of Carrier Status
2006
The VHL tumour-suppressor gene paradigm
1998 StandoutNobel
Familial Medullary Thyroid Carcinoma with Noncysteine RET Mutations: Phenotype-Genotype Relationship in a Large Series of Patients
2001
Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre
2006
Exon 5 of the RET proto-oncogene: A newly detected risk exon for familial medullary thyroid carcinoma, a novel germ-line mutation Gly321Arg
2005
A NovelVal648IleSubstitution inRETProtooncogene Observed in aCys634ArgMultiple Endocrine Neoplasia Type 2A Kindred Presenting with an Adrenocorticotropin-Producing Pheochromocytoma
2002
Genotype-Phenotype Correlations in Hereditary Medullary Thyroid Carcinoma: Oncological Features and Biochemical Properties1
2001
The Use of Preoperative Routine Measurement of Basal Serum Thyrocalcitonin in Candidates for Thyroidectomy due to Nodular Thyroid Disorders: Results from 2733 Consecutive Patients
2010
Unilateral Subtotal Adrenalectomy for Pheochromocytoma in Multiple Endocrine Neoplasia Type 2 Patients
2011
Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma
2015 Standout
Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association
2009 Standout
RET Proto-Oncogene in Sardinia: V804M Is the Most Frequent Mutation and May Be Associated with FMTC/MEN-2A Phenotype
2007
A Rare Extracellular D631Y Germl ine Mutation of the RET Proto-Oncogene in Two Korean Families with Multiple Endocrine Neoplasia 2A
2006
Papillary Thyroid Carcinoma in Patients with RET Proto-Oncogene Germline Mutation
2002
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
2013 Standout
Prophylactic Surgery for Multiple Endocrine Neoplasia Type IIa after Genetic Diagnosis: Is Parathyroid Transplantation Indicated?
1996
Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic
2004
RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors
2006
American Association Of Clinical Endocrinologists, Associazione Medici Endocrinologi, And European Thyroid Association Medical Guidelines For Clinical Practice For The Diagnosis And Management Of Thyroid Nodules
2010 Standout
Pituitary tumors and pregnancy
1978
Medullary Thyroid Carcinoma
1998
von Hippel-Lindau Disease
2006 StandoutNobel
RET Is Constitutively Activated by Novel Tandem Mutations that Alter the Active Site Resulting in Multiple Endocrine Neoplasia Type 2B
2006
Familial Medullary Thyroid Carcinoma: Clinical Variability and Low Aggressiveness Associated withRETMutation at Codon 804
2002
Risk and Penetrance of Primary Hyperparathyroidism in Multiple Endocrine Neoplasia Type 2A Families with Mutations at Codon 634 of the RET Proto-Oncogene
1998
High prevalence of the C634Y mutation in the RET proto-oncogene in MEN 2A families in Spain
1999
Clinical and Genetic Experience in Turkish Multiple Endocrine Neoplasia Type 2 Families
2007
Potency and Tolerance of Calcitonin Stimulation with High-Dose CalciumVersusPentagastrin in Normal Adults
2009
A Novel 9-Base Pair Duplication in RET Exon 8 in Familial Medullary Thyroid Carcinoma1
1999
Pheochromocytoma in MEN 2A Syndrome. Study of 54 Patients
2008
Estimation of Risk of Inherited Medullary Thyroid Carcinoma in Apparent Sporadic Patients
2001
The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis
1996
Review of Multiple Endocrine Neoplasia Type 2A in Children: Therapeutic Results of Early Thyroidectomy and Prognostic Value of Codon Analysis
2003
Exercise as medicine – evidence for prescribing exercise as therapy in 26 different chronic diseases
2015 Standout
Tumor Recurrence and Hypertension Persistence After Successful Pheochromocytoma Operation
1997
Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma.
1996
American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules - 2016 Update Appendix
2016 Standout
Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas.
1995
Guidelines for the management of thyroid cancer
2014 Standout
Appropriate Physical Activity Intervention Strategies for Weight Loss and Prevention of Weight Regain for Adults
2009 Standout
RET Proto-Oncogene in the Development of Human Cancer
1999
MANAGEMENT OF HEREDITARY PHEOCHROMOCYTOMA IN VON HIPPEL-LINDAU KINDREDS WITH PARTIAL ADRENALECTOMY
1999
Role ofVHLGene Mutation in Human Cancer
2004 StandoutNobel
Thyroid carcinoma
2003 Standout
Rapid, nonradioactive screening for mutations in exons 10, 11, and 16 of the RET protooncogene associated with inherited medullary thyroid carcinoma
1997
Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline
2014 Standout
Works of C Houdent being referenced
Phaeochromocytoma in multiple endocrine neoplasia type 2 A: survey of 100 cases
1993
[1-year prognosis of syncope and brief loss of consciousness in patients over 65. A multicenter study of 188 cases].
1988
Results of the calcitonin stimulation test in normal volunteers compared with genetically unaffected members of MEN 2A and familial medullary thyroid carcinoma families.
1997
[Proceedings: Prolactin adenoma revealed by gemellary? pregnancy after clomiphen therapy. Hypophysectomy during 5 th month of pregnancy (author's transl)].
1976
RET mutations in exons 13 and 14 of FMTC patients.
1995
Eating Disorders and Obesity
2008